|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Seven factors were associated with ICAS, as suggested by the meta-analysis, including advanced age (odds ratio (OR) 1.05, 95% CI 1.03-1.08), metabolic syndrome (OR 2.13, 95% CI 1.35-3.37), diabetes mellitus (OR 1.98, 95% CI 1.69-2.31), hypertension (OR 1.97, 95% CI 1.69-2.31), dyslipidemia (OR 1.29, 95% CI 1.04-1.59), high levels of low-density lipoprotein cholesterol (OR 1.06, 95% CI 1.00-1.12) and high levels of apolipoprotein A1 (OR 0.34, 95% CI 0.15-0.75).
|
30658194 |
2019 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Those with remission of hypertension had a significant weight loss (p < 0.001), decrease in body mass index (p < 0.001), 24-h total systolic BP (p = 0.047), baPWV (p = 0.042), triglycerides (p = 0.049) and apolipoprotein B/apolipoprotein A1 (p = 0.004), and an increase in high-density lipoprotein cholesterol (p < 0.001) at 1 year.
|
30317431 |
2019 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
This study investigated the relationship between the MTHFR polymorphism and hypertension and correlated blood lipid indexes, including homocysteine (HCY), lipoprotein (a) [Lp (a)], high-density lipoprotein (HDL), low-density lipoprotein (LDL), apolipoprotein A I (Apo AI), Apo B, glucose (GLU), total cholesterol (TC), and triglyceride (TG), in a Chinese population.
|
25489783 |
2015 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Eight correlations between clinical and epidemiological data and protein expression were noteworthy: diabetes mellitus vs. Ig gamma-2 and apolipoprotein-A1 and albumin; congestive heart failure vs. Ig lambda-2; colonization vs. actin; compressive therapy vs. Ig kappa; systemic arterial hypertension vs. alpha-2-macroglobulin and apolipoprotein-A1; area of ulcer vs. apolipoprotein-A1; race vs. heavy chain Ig and Ig γ-1 chain; age and race vs. Ig γ-1 chain.
|
30261322 |
2019 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
HDL-C (for PVWMLs: OR 0.36, 95% CI 0.19-0.71; for DWMLs: OR 0.35, 95% CI 0.20-0.63) and apoA-1 (for PVWMLs: OR 0.27, 95% CI 0.11-0.66; for DWMLs: OR 0.22, 95% CI 0.10-0.48) were inversely associated with the severity of PVWMLs and DWMLs in women but not in men after adjustment for age, hypertension, diabetes, current smoking, daily drinking, body mass index and uric acid.
|
29162363 |
2018 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein (apo) B, apolipoprotein A-I (apoA-I), LDL particle and HDL particle concentrations were all decreased in PA subjects vs control subjects and subjects with untreated hypertension (P < 0.016).
|
30372543 |
2019 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
The HTN-induced increase in leukocyte and platelet adhesion was attenuated in apolipoprotein A-I transgenic mice (ApoA1-Tg) and blunted in wild-type mice treated with the ApoA1 mimetic peptide, 4F.
|
23281427 |
2013 |
|
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
APOA1 polymorphisms analysis may be a useful tool to identify risk factors for subjects and families and clarify the physiopathological role of these polymorphisms in age-related diseases, such as hypertension and obesity.
|
19408098 |
2009 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microRNA-193-3p.
|
24963038 |
2014 |
|
Hypertensive disease
|
0.700 |
AlteredExpression
|
group |
BEFREE |
The presence of CAD was associated with current, past or passive smoking, a history of diabetes and high blood pressure, a positive family risk factors in this study; levels were below history of CAD, body fat percentage, waist-hip ratio (WHR), low apolipoprotein A1 or low HDL, lipoprotein (a), glucose, insulin, insulin resistance, C-reactive protein (CRP), total cholesterol to HDL ratio (TC/HDL) and creatinine on univariate conditional logistic regression analysis.
|
14741073 |
2004 |
|
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Baseline urinary Hcy-thiolactone/creatinine was significantly associated with plasma tHcy, ApoA1, glomerular filtration rate, potassium and pyridoxal 5'-phosphate (positively) and with age, hypertension, smoking, urinary creatinine, plasma bilirubin and kynurenine (negatively).
|
30193001 |
2019 |
|
Hypoalphalipoproteinemia, Familial
|
0.560 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia.
|
3081805 |
1986 |
|
Hypoalphalipoproteinemia, Familial
|
0.560 |
AlteredExpression
|
disease |
BEFREE |
Dalcetrapib increased high-density lipoprotein cholesterol (HDL-C) and ApoA1 levels to a similar extent in FHA (+22.8, +13.9%) and FCH (+18.4, +12.1%), both p < 0.001 vs. placebo.
|
25281277 |
2014 |
|
Hypoalphalipoproteinemia, Familial
|
0.560 |
GeneticVariation
|
disease |
BEFREE |
Apolipoprotein A-I metabolism in subjects with a PstI restriction fragment length polymorphism of the apoA-I gene and familial hypoalphalipoproteinemia.
|
1981893 |
1990 |
|
Hypoalphalipoproteinemia, Familial
|
0.560 |
GeneticVariation
|
disease |
BEFREE |
These observations show that mutations in ABCA1, APOA1, and LCAT are sufficient to explain >40% of familial hypoalphalipoproteinemia in this cohort.
|
21875686 |
2012 |
|
Hypoalphalipoproteinemia, Familial
|
0.560 |
GeneticVariation
|
disease |
BEFREE |
A complex phenotype in a child with familial HDL deficiency due to a novel frameshift mutation in APOA1 gene (apoA-IGuastalla).
|
26687706 |
2016 |
|
Hypoalphalipoproteinemia, Familial
|
0.560 |
GeneticVariation
|
disease |
BEFREE |
To determine the frequency of familial hypoalphalipoproteinemia in the general population due to mutation of the apolipoprotein A-I (apo A-I) gene, we analyzed sequence variations in the apo A-I gene.
|
9931341 |
1999 |
|
Coronary Arteriosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The proinflammatory enzyme myeloperoxidase induces both oxidative modification and nitrosylation of specific residues on plasma and arterial apolipoprotein A-I to render HDL dysfunctional, which results in impaired ABCA1 macrophage transport, the activation of inflammatory pathways, and an increased risk of coronary artery disease.
|
26323267 |
2016 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
DNA polymorphisms of apolipoprotein A-I/C-III and insulin genes in familial hypertriglyceridemia and coronary heart disease.
|
3115275 |
1987 |
|
Coronary Arteriosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated plasma levels of apolipoproteins A1 (apoA1) and B (apoB) are important protective factors and risk factors, respectively, for atherosclerosis and coronary heart disease.
|
11122500 |
2000 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
High density lipoprotein, apolipoprotein A-I, and coronary artery disease.
|
10942211 |
2000 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results show for the first time an impaired postprandial lipoprotein removal in a case heterozygote with moderately low HDL cholesterol due to an apolipoprotein A-1 mutation not associated with coronary artery disease.
|
9125314 |
1996 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The association between lipoprotein(a) levels, apolipoprotein(a) size and the (TTTTA)(n) polymorphism which is located in the 5' non-coding region of the apo(a) gene was studied in 263 patients with severe coronary heart disease and 97 healthy subjects.
|
11408005 |
2001 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Carriers of the apolipoprotein A-I(Milano) (apoA-I(M)) mutant present with very low plasma HDL cholesterol and moderate hypertriglyceridemia, apparently not leading to premature coronary heart disease.
|
11306522 |
2001 |
|
Coronary Arteriosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
MspI polymorphism at +83 bp in intron 1 of the human apolipoprotein A1 gene is associated with elevated levels of HDL cholesterol and apolipoprotein A1 in nondiabetic subjects but not in type 2 diabetic patients with coronary heart disease.
|
10840998 |
2000 |